

Estrella Immunopharma shares climbed 17.91% after hours following an update on its EB103 cancer therapy trial and early safety results.
You can purchase shares of Estrella Immunopharma (NASDAQ:ESLA) through any online brokerage.
Other companies in Estrella Immunopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Estrella Immunopharma has a consensus price target of $8.00.
The stock price for Estrella Immunopharma (NASDAQ: ESLA) is $0.7056 last updated October 30, 2026 at 9:13 AM EDT.
There are no upcoming dividends for Estrella Immunopharma.
Estrella Immunopharma does not have any upcoming earnings scheduled.
There is no upcoming split for Estrella Immunopharma.
Estrella Immunopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid...